Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2020-08-19 Director's Dealing
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2020-08-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-08-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release with financial results for the second quarter ended June 30, 2020, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length is 3256 characters, which is relatively short and consistent with a regulatory filing announcing an event rather than the full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial data itself.
2020-08-10 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-10 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 20, 2020, by Mustang Bio, Inc. It announces the launch of an at-the-market offering of common stock, including details about the sales agreement and legal opinion attached as exhibits. The content focuses on a capital raising event and related agreements, which aligns with updates on company financing activities. The document length is 4116 characters, which is relatively short but contains substantive information about the financing event itself, not just an announcement of a report. Therefore, it is classified as a Capital/Financing Update (CAP).
2020-07-24 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock, including terms of the offering, use of proceeds, risk factors, and plan of distribution. The document references a sales agreement for an 'at the market' offering and includes information about the company's business and forward-looking statements. This type of document is related to capital raising activities and financing updates rather than financial results, management changes, or regulatory filings. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, supporting a high confidence level.
2020-07-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.